Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana

Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana

ObjectiveTo describe the incidence of adverse events following immunisation (AEFI) and determine the factors that affect the onset and duration of AEFI after COVISHIELD vaccination among healthcare workers.DesignProspective cohort study.SettingTertiary healthcare, Korle-Bu, Ghana.ParticipantThree th...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open Vol. 13; no. 6; p. e061643
Main Authors: Marfoh, Kissinger, Samba, Ali, Okyere, Eunice, Acheampong, Frankline, Owusu, Elsie, Darko, Dorothy Naa Ashokor, Zakariah, Joseph, Mensa, Hillary, Aidoo, Ernestina, Mohammed, Yasmin
Format: Journal Article
Language:English
Published: England British Medical Journal Publishing Group 28-06-2023
BMJ Publishing Group LTD
BMJ Publishing Group
Series:Original research
Subjects:
ChAdOx1 nCoV-19 - adverse effects
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 vaccines
Drug dosages
Ghana - epidemiology
Health Personnel
Humans
Hypersensitivity
Immunization
Immunology
Immunology (including allergy)
Infant
Infections
Medical personnel
Pharmacists
Prospective Studies
Public health
Questionnaires
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Teaching hospitals
Vaccination - adverse effects
Workers
Ghana
COVID-19
Public health
Immunology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectiveTo describe the incidence of adverse events following immunisation (AEFI) and determine the factors that affect the onset and duration of AEFI after COVISHIELD vaccination among healthcare workers.DesignProspective cohort study.SettingTertiary healthcare, Korle-Bu, Ghana.ParticipantThree thousand and twenty-two healthcare workers at least 18 years of age were followed up for 2 months after receiving two doses of the COVISHIELD vaccine.Primary outcomeThe occurrence of the AEFI was identified by self-reporting to the AEFI team members.ResultsA total of 3022 healthcare workers had at least one AEFI (incidence rate of 706.0 (95% CI 676.8 to 736.1) per 1000 doses) with an incidence rate of 703.0 (95% CI 673.0 to 732.0) per 1000 doses for non-serious AEFI and an incidence rate of 3.3 (95% CI 1.6 to 6.1) per 1000 doses for serious AEFI. The most commonly reported systemic adverse events were headache (48.6%), fever (28.5%), weakness (18.4%) and body pains (17.9%). The estimated median time to onset of the AEFI following the first-dose vaccination was 19 hours and the median AEFI duration was 40 hours or 2 days. Delayed-onset AEFI occurred in 0.3% after first dose and 0.1% after second dose. Age, sex, previous SARS-CoV-2 infection, history of allergies and comorbidity were not significantly associated with the onset and duration of AEFI. However, participants who used paracetamol seemed to be significantly protected (HR 0.15; 95% CI 0.14, 0.17) from having a long duration of AEFI.ConclusionThe results of our study indicate a high incidence of non-serious AEFI and the rare occurrence of serious AEFI after COVISHIELD vaccination in healthcare workers. The rate of AEFI was higher after the first dose than after the second dose. Sex, age, previous SARS-CoV-2 infection, allergies and comorbidity were not significantly associated with the onset and duration of AEFI.
Bibliography:Original research
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2022-061643